Scholarlink

Background and objective <p>Prostate cancer progresses to metastatic castration-resistant prostate cancer (mCRPC) in 30–40% of patients after surgery and/or radiotherapy, with a poor prognosis and short overall survival (OS). Ra-223 therapy improves OS, progression-free survival (PFS), reduces symptomatic skeletal events (SSE), bone metastasis-related pain, and PSA/ALP responses. Although some studies show OS gains, systematic reviews are inconsistent. This meta-analysis synthesizes prior data to evaluate Ra-223’s impact on OS and overall efficacy.</p> Methods <p>A comprehensive and systematic search of the databases of PubMed/MEDLINE and Cochrane Library was performed to retrieve original articles published until March 10, 2023. Two authors independently reviewed the titles and abstracts of the retrieved articles based on the inclusion and exclusion criteria.</p> Result <p>Among 7 studies (<i>n</i> = 4035) in the quantitative analysis, 1894 participants received Ra-223. The pooled median OS with Ra-223 was 15.08 months (95% CI: 10.9–22.7), not significantly different from standard therapy (MSR 1.38, 95% CI: 0.89–2.15, <i>p</i> = 0.154). Pooled median PFS was longer with Ra-223 (6.3 months, 2.8–9.86) versus standard therapy (3.7 months, 3.3–4.1). Pooled median time to SSE incidence was also longer with Ra-223 (24.7 months, 15.6–33.9) than with standard therapy (17.5 months, 9.8–24.7).</p> Conclusion <p>Although the overall survival benefit of Ra-223 is not yet definitive, its ability to delay disease progression and skeletal events supports its role in mCRPC management. Further research optimizing patient selection and Ra-223 combination regimens could enhance outcomes in advanced prostate cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical efficacy of radium-223 in simulating real-world clinical practice: a meta-analysis

  • 期刊论文

  • 发表日期：

    2026年3月28日

查看全文
  • Yen-Hsiang Chang,
  • Li Yu Chen,
  • Ya Ting Huang,
  • Hao Lun Luo

摘要

Background and objective

Prostate cancer progresses to metastatic castration-resistant prostate cancer (mCRPC) in 30–40% of patients after surgery and/or radiotherapy, with a poor prognosis and short overall survival (OS). Ra-223 therapy improves OS, progression-free survival (PFS), reduces symptomatic skeletal events (SSE), bone metastasis-related pain, and PSA/ALP responses. Although some studies show OS gains, systematic reviews are inconsistent. This meta-analysis synthesizes prior data to evaluate Ra-223’s impact on OS and overall efficacy.

Methods

A comprehensive and systematic search of the databases of PubMed/MEDLINE and Cochrane Library was performed to retrieve original articles published until March 10, 2023. Two authors independently reviewed the titles and abstracts of the retrieved articles based on the inclusion and exclusion criteria.

Result

Among 7 studies (n = 4035) in the quantitative analysis, 1894 participants received Ra-223. The pooled median OS with Ra-223 was 15.08 months (95% CI: 10.9–22.7), not significantly different from standard therapy (MSR 1.38, 95% CI: 0.89–2.15, p = 0.154). Pooled median PFS was longer with Ra-223 (6.3 months, 2.8–9.86) versus standard therapy (3.7 months, 3.3–4.1). Pooled median time to SSE incidence was also longer with Ra-223 (24.7 months, 15.6–33.9) than with standard therapy (17.5 months, 9.8–24.7).

Conclusion

Although the overall survival benefit of Ra-223 is not yet definitive, its ability to delay disease progression and skeletal events supports its role in mCRPC management. Further research optimizing patient selection and Ra-223 combination regimens could enhance outcomes in advanced prostate cancer.